Drug Approval | April 15, 2023
NS Pharma announces FDA clearance to initiate phase II study for an Exon 44 skipping candidate
Study efficacy measures will include the expression of dystrophin protein and motor function.
Study efficacy measures will include the expression of dystrophin protein and motor function.
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
The session took place in the presence of Union Ministers Hardeep Singh Puri and Gen V K Singh along with Anil Agarwal, Rajya Sabha Member of Parliament
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
He mentioned that Thyroid disorders are a common health problem in Jammu and Kashmir
Government hospitals like AIIMS, KGMC & many more as per day OPD patients are 18-25 thousand
Successes under Ayushman Bharat Digital Health Mission and Pradhan Mantri National Dialysis Programme highlighted
For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
Subscribe To Our Newsletter & Stay Updated
